Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
OrthoPediatrics Corp. is a pediatric-focused medical device company that designs, develops, and markets orthopedic implants and instruments exclusively for children. The company operates within the medical devices and orthopedic surgery industries, with a specialization in addressing the anatomical and clinical needs of skeletally immature patients. Its products are used primarily by pediatric orthopedic surgeons to treat trauma, deformity, scoliosis, and other musculoskeletal conditions.
The company’s primary revenue drivers are its surgical implant systems, which include trauma and deformity correction products, scoliosis systems, and sports medicine solutions tailored for pediatric patients. OrthoPediatrics is differentiated by its exclusive focus on pediatrics, a segment historically underserved by adult-scaled orthopedic products. Founded in 2006, the company evolved from a niche product developer into a publicly traded company following its 2017 initial public offering, expanding its portfolio through internal development and acquisitions.
Business Operations
OrthoPediatrics generates revenue through the sale of orthopedic implants, surgical instruments, and related systems to hospitals and ambulatory surgery centers. Its operating segments are organized around product categories rather than formal reporting segments, with core business lines including Trauma & Deformity, Scoliosis, Sports Medicine, and Orthobiologics. Sales are primarily driven through a specialized direct sales force and distributor relationships focused on pediatric orthopedic specialists.
The company operates domestically in the United States and internationally through subsidiaries and distribution partners. Key subsidiaries include OrthoPediatrics US, LLC, Pega Medical (acquired in 2022), and ApiFix Ltd. (acquired in 2023). OrthoPediatrics controls proprietary implant designs, instrument sets, and surgeon-specific systems, with manufacturing largely outsourced to qualified third-party suppliers under regulated quality systems.
Strategic Position & Investments
OrthoPediatrics’ strategy centers on expanding its comprehensive pediatric orthopedic platform through targeted acquisitions, surgeon-driven product innovation, and international expansion. Growth initiatives emphasize increasing procedural coverage per surgeon, entering adjacent pediatric subspecialties, and leveraging its sales infrastructure to cross-sell newly acquired technologies.
Major investments include the acquisitions of Pega Medical, which strengthened its trauma and deformity portfolio, and ApiFix Ltd., which added a motion-preserving scoliosis correction system. The company has also invested in MiRus LLC, supporting continued innovation in pediatric spine solutions. Emerging areas of focus include minimally invasive scoliosis treatments and pediatric-specific sports medicine implants, reflecting demand for less invasive and growth-friendly surgical options.
Geographic Footprint
OrthoPediatrics is headquartered in Warsaw, Indiana, United States, a major hub for orthopedic device manufacturing and innovation. The company maintains a strong market presence across North America, which represents the majority of its revenue, supported by a direct sales organization.
Internationally, OrthoPediatrics operates across Europe, Asia-Pacific, Latin America, and parts of the Middle East, primarily through subsidiaries and third-party distributors. The acquisition of Pega Medical, based in France, and ApiFix, based in Israel, expanded its operational and commercial footprint in Europe and strengthened its global research and development capabilities.
Leadership & Governance
OrthoPediatrics is led by a management team with extensive experience in orthopedic medical devices and pediatric-focused innovation. The company emphasizes a surgeon-centric philosophy, prioritizing clinical collaboration, long-term product development, and ethical growth over short-term market expansion.
Key executives include:
- David A. Bailey – President and Chief Executive Officer
- John B. LeCann – Executive Vice President and Chief Financial Officer
- Patrick J. Flynn – Executive Vice President, Global Sales
- Jason Kraus – Executive Vice President, Global Operations
- Elizabeth Keane – Executive Vice President, Clinical Affairs and Strategy
The board and executive leadership oversee governance practices aligned with public company standards, with strategic oversight informed by clinical expertise, regulatory compliance, and long-term value creation for stakeholders.